EP0145390A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
A method for producing non-glycosylated human interleukin-2 protein
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1984-11-23
•
Granted: —
•
Expires: 2004-11-23
Abstract
Abstract A substantially pure non-glycosylated human interleukin-2 protein having a specific activity of not less than 10<4> U/mg is obtained by growing a transformant carrying a DNA having a base sequence coding for human interleukin-2 to cause production and accumulation of human interleukin-2 in the culture broth, and subjecting the thus obtained human interleukin-2-containing liquid to a purification process comprising a hydropholic column chromatography.
Inventors
- 👤 Koichi Kato
- 👤 Takao Yamada
- 👤 Haruo Onda
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-01 17:11
CPC Classifications
C; C12; C12N; C12N9/00; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/54; C07K14/55; A; A61; A61P; A61P35/00; A61P37/00; A61P37/02; A61P37/04; C12N15/00; A61K; A61K38/00
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
70 words
AUSTRIAN CLAIMS 1. A method of producing a substantially pure non-glycosylated human interleukin-2 protein having a specific activity of not less than 10 4 U/mg, which comprises growing a transformant carring a DNA having a base sequence coding for human interleukin-2 to cause production and accumulation of human interleukin-2 in the culture broth and subjecting the thus obtained human interleukin-2-containing liquid to a purification process comprising a hydrophobic column chromatography.
Claim 2
Dependent Claim
22 words
A method according to claim 1, wherein the hydrophobic column chromatography is a high performance liquid chromatography using a reversed phase column.
Claim 3
Dependent Claim
20 words
A method according to claim 2, wherein the chromatography is conducted by using an eluent of pH 1.5 to 8.
Claim 4
Dependent Claim
20 words
A method according to claim 2, wherein the ,chromatography is conducted under a flow rate of 0.1 to 100 ml/min.
Claim 5
Dependent Claim
33 words
A method according to claim 1, wherein the human interleukin-2 is produced and accumulated in the grown transformant cells and the human interleukin-2 is extracted from the cells to obtain human interleukin-2-containing liquid.
Claim 6
Dependent Claim
19 words
A method according to claim 5, wherein the human interleukin-2 is extracted with a solution of protein- denaturing agent.
Claim 7
Dependent Claim
27 words
A method according to claim 6, wherein the human interleukin-2 is extracted with a solution of a guanidine salt in a concentration of 2 to 8 M.
Claim 8
Dependent Claim
32 words
A pharmaceutical composition which contains a substantially pure non-glycosylated human interleukin-2 protein having a specific activity of not less than 10 4 U/mg and a pharmaceutically acceptable carrier, vehicle or diluent therefor.
Claim 9
Dependent Claim
25 words
A composition according to claim 8, wherein the human interleukin-2 protein has :a amino acid sequence of the formula: wherein X is Met or hydrogen.
Claim 10
Dependent Claim
16 words
A composition according to claim 8 wherein the human interleukin-2 protein is in a lyophilized form.
Claim 11
Dependent Claim
11 words
A composition according to claim 8, which is an injectable preparation.
Claim 12
Independent Claim
40 words
A method of producing a pharmaceutical composition containing a substantially pure non-glycosylated human interleukin-2 protein having a specific activity of not less than 10 4 U/mg, which comprises admixing said protein with a pharmaceutically acceptable carrier, vehicle or diluent therefor.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.